



Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Inclusion Criteria*

Neurologic deficit (based on history or exam) attributed to focal brain ischemia and EITHER:

- high risk TIA: complete resolution of the deficit at the time of randomization AND ABCD² score ≥ 4 **OR**
- minor ischemic stroke: residual deficit with NIHSS ≤ 3 at the time of randomization.

Ability to randomize within 12 hours of time last known free of new ischemic symptoms.

Head CT or MRI ruling out hemorrhage or other pathology, such as vascular malformation, tumor or abscess, that could explain symptoms or contraindicate therapy.

Ability to tolerate aspirin at a dose of 50-325 mg/day.

POINT Hotline (Outside US):
Your country exit code + 1-415-663-4444

POINT Hotline (US):
1-866-94-POINT (1-866-947-6468)

POINT is supported by funding from the NINDS.